G1 Therapeutics, Inc.
Simbols: GTHX
NASDAQ
4.44
USDTirgus cena šodien
-7.4160
P/E koeficients
-0.3307
PEG koeficients
232.23M
MRK Cap
- 0.00%
DIV ienesīgums
G1 Therapeutics, Inc. (GTHX) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 345.99 | 82.2 | 145.1 | 221.2 | ||||||||||
balance-sheet.row.short-term-investments | 185.28 | 49.9 | 50.5 | 0 | ||||||||||
balance-sheet.row.net-receivables | 46.78 | 12.7 | 11.1 | 5.7 | ||||||||||
balance-sheet.row.inventory | 54.08 | 12.4 | 16.2 | 3.5 | ||||||||||
balance-sheet.row.other-current-assets | 30.42 | 7.6 | 7.1 | 13.2 | ||||||||||
balance-sheet.row.total-current-assets | 477.33 | 114.9 | 179.5 | 243.6 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 26.32 | 6.4 | 8 | 9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0.62 | 0.2 | 0.3 | 0.3 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.28 | 0 | 0.3 | 1.2 | ||||||||||
balance-sheet.row.total-non-current-assets | 27.23 | 6.6 | 8.5 | 10.5 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 504.55 | 121.5 | 188 | 254.1 | ||||||||||
balance-sheet.row.account-payables | 22.2 | 4 | 7.4 | 2.9 | ||||||||||
balance-sheet.row.short-term-debt | 31.9 | 1.3 | 1.1 | 1.1 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 116.16 | 51.6 | 82.6 | 81.9 | ||||||||||
Deferred Revenue Non Current | 2 | 0.5 | 1 | 1 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -46.6 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 73.94 | 23.8 | 27 | 23.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 210.97 | 56.4 | 83.6 | 82.9 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 18.01 | 4.3 | 6.8 | 7.9 | ||||||||||
balance-sheet.row.total-liab | 340.86 | 86.2 | 119.2 | 110.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.02 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -3090.2 | -780 | -732 | -584.5 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 2441.74 | 815.4 | 800.8 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -307.57 | 121.5 | 188 | -473.9 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -307.57 | - | - | - | ||||||||||
Total Investments | 185.47 | 50.1 | 50.5 | 0.3 | ||||||||||
balance-sheet.row.total-debt | 127.72 | 57.2 | 83.8 | 83.1 | ||||||||||
balance-sheet.row.net-debt | -74.71 | 24.9 | -10.8 | -138.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -30.59 | -48 | -147.6 | -148.4 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0.5 | 0.5 | 0.5 | 0.5 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 1.2 | 0 | 0.6 | ||||||||||
cash-flows.row.stock-based-compensation | 10.67 | 14.5 | 20.6 | 22.3 | ||||||||||
cash-flows.row.change-in-working-capital | 1.14 | -5.2 | -5.3 | -8.8 | ||||||||||
cash-flows.row.account-receivables | 4.37 | -1.6 | -5.4 | -5.5 | ||||||||||
cash-flows.row.inventory | 3 | 3.7 | -12.7 | -3.5 | ||||||||||
cash-flows.row.account-payables | -0.37 | -3.4 | 4.4 | -0.7 | ||||||||||
cash-flows.row.other-working-capital | -4.26 | -4 | 8.4 | 0.8 | ||||||||||
cash-flows.row.other-non-cash-items | 9.12 | -1.4 | 3.1 | 1.7 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -18.18 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 50 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -116.81 | -124.7 | -65 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 122 | 127.5 | 15 | 0 | ||||||||||
cash-flows.row.other-investing-activites | -0.1 | 0 | -50 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 5.19 | 2.8 | -50.5 | 0 | ||||||||||
cash-flows.row.debt-repayment | -26.69 | -26.7 | 0 | -53.6 | ||||||||||
cash-flows.row.common-stock-issued | -0.01 | -0.2 | 52.4 | 86.4 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -8.76 | -0.3 | 0.1 | 113.1 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -35.42 | -26.9 | 52.5 | 145.9 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -48.41 | -62.4 | -126.7 | 13.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 161.52 | 32.3 | 94.9 | 221.6 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 209.93 | 94.7 | 221.6 | 207.8 | ||||||||||
cash-flows.row.operating-cash-flow | -18.18 | -38.3 | -128.6 | -132.1 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | -18.18 | -38.3 | -129.1 | -132.1 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 84.04 | 82.5 | 51.3 | 31.5 | ||||||||||
income-statement-row.row.cost-of-revenue | 6.82 | 7.2 | 3.7 | 2 | ||||||||||
income-statement-row.row.gross-profit | 77.23 | 75.3 | 47.6 | 29.5 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 35.55 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.operating-expenses | 102.6 | 114.8 | 183.7 | 171.9 | ||||||||||
income-statement-row.row.cost-and-expenses | 106.34 | 122 | 187.5 | 173.9 | ||||||||||
income-statement-row.row.interest-income | 2.04 | 2.5 | 0.7 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.total-operating-expenses | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0.51 | 0.5 | 1.3 | -0.3 | ||||||||||
income-statement-row.row.ebitda-caps | -21.23 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -22.83 | -39.5 | -136.2 | -142.5 | ||||||||||
income-statement-row.row.income-before-tax | -27.48 | -44.9 | -145.9 | -147.4 | ||||||||||
income-statement-row.row.income-tax-expense | 3.12 | 3.1 | 1.7 | 0.9 | ||||||||||
income-statement-row.row.net-income | -30.59 | -48 | -147.6 | -148.4 |
Biežāk uzdotie jautājumi
Kas ir G1 Therapeutics, Inc. (GTHX) kopējie aktīvi?
G1 Therapeutics, Inc. (GTHX) kopējie aktīvi ir 121540000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 29349000.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.919.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.356.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -0.364.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -0.272.
Kāda ir G1 Therapeutics, Inc. (GTHX) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -47967000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 57173000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 114843000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 19887000.000.